Deutetrabenazine shows long‐term effectiveness for tardive dyskinesia
The Brown University Psychopharmacology Update2019Vol. 30(11), pp. 4–4
Abstract
Deutetrabenazine, which has been shown to improve symptoms of tardive dyskinesia (TD) in two 12‐week trials, now has demonstrated longer‐term efficacy and safety. The latest results were found in open‐label extensions of the Aim to Reduce Movements in Tardive Dyskinesia (ARM‐TD) and Addressing Involuntary Movements in Tardive Dyskinesia (AIM‐TD) trials.
Related Papers
- → Effects of Age on a New Animal Model of Tardive Dyskinesia(1997)47 cited
- → Prevalence of tardive dyskinesia in samples of elderly people in Hong Kong(1993)13 cited
- → Neuroleptic induced dyskinesia or…?(2015)
- Efficacy of Vitamin E treatment on haloperidol-induced tardive dyskinesia model rats(2004)